Elevated levels of the mediator of catabolic bone remodeling rankl in the bone marrow environment link chronic heart failure with osteoporosis

Circulation: Heart Failure

Volumn 5, Issue 6, 2012, Pages 769-777

  Leistner, David M ^a   Seeger, Florian H ^a   Fischer, Ariane ^a,b,c   Röxe, Tino ^a,b,c   Klotsche, Jens ^a,b,g   Iekushi, Kazuma ^a,b,c   Seeger, Timon ^a   Assmus, Birgit ^a   Honold, Jörg ^a   Karakas, Mahir ^a   Badenhoop, Klaus ^a,b,d   Frantz, Stefan ^a,e,f   Dimmeler, Stefanie ^a,b,c   Zeiher, Andreas M ^b  

^a Department of Medicine III ^*  (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Institute for Cardiovascular Regeneration   (Germany)

^d Marienhospital Stuttgart   (Germany)

^e Endocrinology Department of Medicine I ^*  (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g Institute for Clinical Psychology and Psychotherapy   (Germany)

Author keywords

Bone marrow; Heart failure; OPG; Osteoporosis; RANKL

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; ARTICLE; BONE MARROW; BONE REMODELING; BONE TURNOVER; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; OSTEOCLAST; OSTEOPOROSIS; POSTINFARCTION HEART FAILURE; PRIORITY JOURNAL;

AGED; ANIMALS; BIOLOGICAL MARKERS; BONE MARROW; BONE REMODELING; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELLS, CULTURED; CHRONIC DISEASE; COHORT STUDIES; COLLAGEN TYPE I; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HEART FAILURE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; PEPTIDES; RANK LIGAND; REGRESSION ANALYSIS;

EID: 84873694160     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.111.966093     Document Type: Article

References (29)

1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397-1402.
2. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365:1877-1889.
3. van Diepen S, Majumdar SR, Bakal JA, McAlister FA, Ezekowitz JA. Heart failure is a risk factor for orthopedic fracture: A population-based analysis of 16,294 patients. Circulation. 2008;118:1946-1952.
4. Lyons KJ, Majumdar SR, Ezekowitz JA. The unrecognized burden of osteoporosis-related vertebral fractures in patients with heart failure. Circ Heart Fail. 2011;4:419-424.
5. Seeman E. Pathogenesis of bone fragility in women and men. Lancet. 2002;359:1841-1850.
6. Sennerby U, Melhus H, Gedeborg R, Byberg L, Garmo H, Ahlbom A, Pedersen NL, Michaëlsson K. Cardiovascular diseases and risk of hip fracture. JAMA. 2009;302:1666-1673.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
8. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
9. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17-25.
10. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104:271-280.
11. Kissel CK, Lehmann R, Assmus B, Aicher A, Honold J, Fischer-Rasokat U, Heeschen C, Spyridopoulos I, Dimmeler S, Zeiher AM. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol. 2007;49:2341-2349.
12. Orlandi A, Chavakis E, Seeger F, Tjwa M, Zeiher AM, Dimmeler S. Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res Cardiol. 2010;105:703-712.
13. Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M, Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12:657-664.
14. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124:407-421.
15. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514-520.
16. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
17. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-878.
18. Law PH, Sun Y, Bhattacharya SK, Chhokar VS, Weber KT. Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol. 2005;46:142-146.
19. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-2468.
20. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009;29:975-980.
21. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633.
22. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009;45:669-676.
23. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res. 2000;15:1526-1536.
24. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res. 1993;8:127-132.
25. Withold W. Monitoring of bone turnover biological, preanalytical and technical criteria in the assessment of biochemical markers. Eur J Clin Chem Clin Biochem. 1996;34:785-799.
26. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/RANKL system: A bone key to vascular disease. Expert Rev Cardiovasc Ther. 2006;4:801-811.
27. Carbone L, Buzková P, Fink HA, Lee JS, Chen Z, Ahmed A, Parashar S, Robbins Jr. Hip fractures and heart failure: Findings from the Cardiovascular Health Study. Eur Heart J. 2010;31:77-84.
28. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
29. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med. 2009;361:818-820.